Skip to main content

Advertisement

Table 3 Phenotype frequencies of HLA-ABDR alleles for severe and mild groups

From: The association of human leukocyte antigen polymorphisms with disease severity and latency period in patients with silicosis

HLA alleles Severe group (n = 28 patients)** Mild group (n = 20 patients)** P= Mean
A1 5 (8.9%) 4 (10.0%)   NS*
A2 16 (28.6%) 6 (15.0%)   NS*
A3 5 (8.9%) 2 (5.0%)   NS*
A11 10 (17.9%) 6 (15.0%)   NS*
A23 0 (0.0%) 3 (7.5%) 0.069 Borderline
A24 12 (21.4%) 11 (27.5%)   NS*
A26 3 (5.4%) 1 (2.5%)   NS*
A29 1 (1.8%) 2 (5.0%)   NS*
A30 2 (3.6%) 3 (7.5%)   NS*
A32 1 (1.8%) 1 (2.5%)   NS*
A33 0 (0.0%) 1 (2.5%)   NS*
A68 1 (1.8%) 0 (0.0%)   NS*
B7 5 (8.9%) 3 (7.5%)   NS*
B8 2 (3.6%) 1 (2.5%)   NS*
B13 2 (3.6%) 1 (2.5%)   NS*
B18 3 (5.4%) 0 (0.0%)   NS*
B27 1 (1.8%) 0 (0.0%)   NS*
B35 17 (30.4%) 13 (32.5)   NS*
B37 1 (1.8%) 1 (2.5%)   NS*
B38 1 (1.8%) 0 (0.0%)   NS*
B39 1 (1.8%) 1 (2.5%)   NS*
B40 1(1.8%) 3 (7.5%)   NS*
B41 1(1.8%) 1 (2.5%)   NS*
B44 4 (7.1%) 0 (0.0%)   NS*
B49 0 (0.0%) 3 (7.5%) 0.069 Borderline
B50 2 (3.6%) 0 (0.0%)   NS*
B51 4 (7.1%) 10 (25.0%) 0.016 Significant
B52 3 (5.4%) 0 (0.0%)   NS*
B54 1 (1.8%) 0 (0.0%)   NS*
B55 5 (8.9%) 0 (0.0%) 0.062 Borderline
B57 2 (3.6%) 2 (5.0%)   NS*
B64 0 (0.0%) 1 (2.5%)   NS*
DR3 4 (7.1%) 2 (5.0%)   NS*
DR4 10 (17.9%) 2 (5.0%) 0.055 Borderline
DR7 5 (8.9%) 3 (7.5%)   NS*
DR10 2 (3.6%) 2 (5.0%)   NS*
DR11 12 (21.4%) 11 (27.5%)   NS*
DR13 4 (7.1%) 7 (17.5%)   NS*
DR14 5 (8.9%) 6 (15.0%)   NS*
DR15 9 (16.1%) 5 (12.5%)   NS*
DR16 5 (8.9%) 2 (5.0%)   NS*
  1. *NS, Not significant; ** Percentages were calculated according to the allele number.